A new study has found that a combination of two drugs could enhance the immune system to treat one of the most common types of cancer in the world, bowel cancer. Also known as colorectal cancer, despite its widespread presence, the treatment options for this condition are limited. What the study specifically found was that this procedure could shrink the tumours caused by this condition by around 60%.

What Are The Drugs Involved

The trial involved the use of two immunotherapy drugs, botancilimab and balstilumab. It is a monoclonal antibody that works to stimulate the body's immune system to attack cancer. The study is a rather significant find, as it’s the first time that a consistent and durable response to immunotherapy has been reported in patients with solid MSS mCRC tumours.

The study was divided into several phases for more than 6 months. In the US trial, around around 101 patients with microsatile stable metastatic colorectal (MSS-mCRC) tumours showed a decrease . Around 61% of the patients experienced tumour shrinkage or stabilization after combined treatment with votancilumab and balstilumab. When it comes to downsides, diarrhea and fatigue were found to be the most common side effects or side effects of this drug.

These results are interesting and open to exploration. To date, immunotherapy has not been effective in patients with CNS-mCRC tumors. This study demonstrates the potential of the combination of botenlimab and balstilimab in the treatment of CNS mCRC, providing new hope for people diagnosed with colon cancer.

What Could This Mean For Bowel Cancer Treatment In The Future

The study is currently in the final stages of clinical trials, and the US Food and Drug Administration (FDA) hopes to quickly gain approval for its use because of the importance of this area that affects many people. The efficiency shown demonstrates the potential of botansilimab to contribute to broad antitumor immunity.

All in all, the combination of botensilimab and balstilimab represents a promising new direction in the treatment of colorectal cancer. This breakthrough could improve conditions for many patients worldwide and lights a new hope in the fight against this common disease. The results of this study show the effectiveness of immunotherapy in this field and how its potential to transform cancer treatment can only grow in the years to come.

In a bid to ensure safe healthcare environments, India's Ministry of Health and Family Welfare (MoHFW) has launched a nationwide Fire Safety Week across healthcare facilities.

The Fire Safety Week will be observed from May 4 to May 10 across the country. The theme of this year’s Fire Safety Week is “Safe Schools, Safe Hospitals, and a Fire-Safety Aware Society: Together for Fire Prevention”.

Fire safety in healthcare facilities is a critical component of patient safety and health system resilience. Hospitals house vulnerable patients, high electrical loads, oxygen-rich environments, and complex medical equipment, making them particularly susceptible to fire hazards.

"Fire Safety Week provides an important opportunity to reassess existing infrastructure, evaluate whether facilities have been adequately audited, and identify gaps and discrepancies that need to be addressed," said Union Health Secretary, Punya Salila Srivastava, while launching the initiative.

Emphasizing capacity building, she stressed that healthcare professionals must be adequately trained and sensitized to effectively respond to fire emergencies.

How Will Fire Safety Week Be Conducted?

The nationwide campaign is designed to go beyond awareness and focus on actionable preparedness. States and healthcare institutions will:

• Conduct mock fire drills to test evacuation readiness
• Train staff in handling fire extinguishers and emergency protocols
• Review infrastructure such as alarms, sprinklers, and exits
• Promote compliance with fire safety norms
• Such drills have already shown impact in local initiatives. Additionally, capacity-building exercises will help administrators identify vulnerabilities and implement corrective measures.

Recognizing the increasing need to strengthen preparedness and ensure continuity of healthcare services during emergencies, the Health Ministry has also developed the National Guidelines on Fire and Life Safety in Healthcare Facilities (2026). This is a revised version of the Fire and Life Safety Guideline (2020).

What Do The Revised Guidelines Say

The primary objective of the guidelines is to provide a standardized and practical framework to strengthen fire prevention and response mechanisms in healthcare facilities. Key features of the revised guidelines include:

• Strengthened governance framework: The 2026 guidelines introduce clearly defined institutional roles, responsibilities, and committee structures, strengthening accountability beyond the action-oriented approach of the 2020 guidelines.
• Introduction of structured risk assessment approach: The guidelines incorporate systematic fire hazard assessment and risk categorization, enabling prioritization of safety measures based on vulnerability.
• Improved patient-centric evacuation planning: It expands evacuation planning with specialized protocols for vulnerable patient groups such as ICU, NICU, PICU, and operation theatre patients.
• Expanded coverage of fire safety infrastructure systems: It provides more comprehensive guidance on fire detection, suppression, electrical safety, medical gas systems, HVAC integration, and smoke management.
• Training and capacity building framework: It formalizes structured training programs, mock drills, and role-based preparedness mechanisms for healthcare personnel.
• Inclusion of detailed operational annexures: It introduced expanded annexures covering unit-specific (ICU, NICU, etc.) safety practices, evacuation methods, and fire safety equipment requirements.
• Strengthened institutional preparedness mechanisms: The guidelines integrate preparedness across governance, infrastructure, and response systems to enhance readiness during emergencies.
• Promotion of a safety-oriented organizational culture: It emphasizes continuous monitoring, periodic audits, and awareness activities to institutionalize long-term fire safety practices.

These guidelines are expected to:

• Strengthen fire safety preparedness across public and private healthcare facilities
• Reduce risk of fire-related incidents and associated loss of life
• Improve the safety of patients, healthcare workers, and visitors
• Enhance continuity of essential health services during emergencies
• Promote fire safety practices across states and union territories.

Amid rising obesity, early diabetes risk, and mental health issues among children, India has expanded its child health screening program to include behavioral disorders and non-communicable disease (NCD) risk factors.

The Ministry of Health and Family Welfare rolled out the screening measures under the revised Rashtriya Bal Swasthya Karyakram (RBSK) 2.0 guidelines.

The guidelines include steps to address mental health conditions and early risk factors for diseases such as diabetes and hypertension. These were released at the recently concluded National Summit on Good Practices and Innovations in Public Healthcare Service Delivery.

The screening services are free and will be delivered through mobile health teams at Anganwadi centers and schools, ensuring universal outreach and early identification.

What Does The RBSK 2.0 Guideline Include?

• The guidance document establishes, for the first time, a structured and standardized national framework for the screening, diagnosis, treatment, and long-term management of childhood diabetes. It calls for universal screening of all children from birth to 18 years.

• Suspected cases will undergo immediate blood glucose testing and timely referral to district-level health facilities for confirmatory diagnosis and treatment.

• A free-of-cost care package will be available at public health facilities. This includes screening, diagnostic services, lifelong insulin therapy, monitoring devices such as glucometers and test strips, and regular follow-up care. This will reduce the financial burden and ensure uninterrupted treatment for children diagnosed with diabetes.

• The initiative promotes the “4Ts” awareness framework—Toilet, Thirsty, Tired, and Thinner—enabling parents, teachers, and caregivers to recognize early warning signs of Type 1 diabetes.

• The document also emphasizes the need to provide structured training on insulin administration, blood glucose monitoring, emergency response, and daily disease management. It outlines evidence-based treatment guidelines, regular monitoring schedules, and protocols for preventing complications.

• RBSK 2.0 introduces digital health cards, real-time data systems, and integrated platforms for tracking, monitoring, and service delivery. These digital innovations are expected to enhance program efficiency, accountability, and evidence-based decision-making across all levels of implementation.

Signs Of Diabetes In Children

Children with Type 1 Diabetes Mellitus can develop diabetic ketoacidosis (DKA) if it is not diagnosed on time, since they are insulin-dependent.

Dr. Archana Arya, Senior Consultant Pediatric & Adolescent Endocrinologist at the Institute of Child Health, Sir Ganga Ram Hospital, New Delhi, told HealthandMe that DKA requires hospitalization for treatment, and if undiagnosed, it can lead to coma and death. Early diagnosis reduces morbidity and hospital admissions.

These children present with typical symptoms such as

• increased thirst,
• frequent urination,
• weight loss.

Type 2 Diabetes Mellitus may or may not present with typical symptoms, and children may develop long-term complications such as retinopathy and nephropathy if the condition goes undiagnosed for a prolonged period.

All overweight and obese children, especially those with a family history of Type 2 diabetes, those with acanthosis nigricans (thickened and dark skin behind the neck and underarms), and girls with PCOS are at high risk of developing Type 2 diabetes and should be screened annually to prevent complications.

The expert added that children with diabetes are at a higher risk of depression (2–3 times higher prevalence), anxiety, and suicidal ideation (in 8–27 percent of youth) due to dietary restrictions and the burden of multiple insulin injections in Type 1 diabetes. Diabetic youth are 1.7 times more likely to attempt suicide, often through insulin overdose.

Why Is The Initiative Important?

Dr. Seema Dhir, Unit Head & Senior Consultant, Internal Medicine, Artemis Hospitals, told HealthandMe that good health in early life is essential for preventing non-communicable diseases such as obesity, diabetes, and heart disease. Diabetes is often linked to poor lifestyle and health choices.

Early monitoring, detection, and effective management can reduce the growing burden of diabetes.

Dr. Munia Bhattacharya, Senior Consultant – Clinical Psychology, Mental Health and Behavioural Sciences, Marengo Asia Hospitals, Gurugram, emphasized that preventing non-communicable diseases like diabetes, heart disease, and obesity begins with maintaining both mental and physical well-being.

Providing mental support to children helps them cope better with stress and reduces the risk of anxiety, depression, and suicidal thoughts.

Children who are encouraged to express their feelings and seek help are less likely to experience anxiety, depression, and suicidal tendencies. Early awareness also builds coping skills, decision-making abilities, and healthier lifestyles—paving the way for long-term well-being and a more balanced, confident future.

Cancer treatment is often viewed as months of painful chemotherapy, radiotherapy, and surgeries that one might physically recover from but may continue to struggle with the trauma of for years. But now, thanks to a new injectable drug, cancer treatment may speed up for thousands of NHS patients in the UK. Pembrolizumab, also known as Keytruda, is that one-minute cancer drug injection that will likely speed up cancer treatment for thousands of patients—and soon, it will be available as a quicker jab instead of a half-hour drug.

What is pembrolizumab?

Pembrolizumab is an injectable drug prescribed to over 14,000 people in Britain every year. It works by stimulating the immune system to attack cancer cells on its own. Patients usually spend about two hours at a clinic when it is slowly administered for 30 minutes or more via a drip or IV line. However, this one-minute jab is now available in an injectable form and can be administered every three weeks or as a two-minute injection every six weeks.

Also Read: WHO Says Suspected Hantavirus Killed 3 on Cruise Ship: Symptoms, Risks, and Prevention

The drug has now been made more concentrated, with an extra component added to help the body absorb it faster. This shot is given in the stomach or the thigh instead of being infused through a vein in the arm. Doctors say that this rapid jab, which takes less than a minute to deliver, can help patients get back to their lives without having to spend hours in a hospital chair; for a cancer patient, regular hospital trips and multiple rounds of therapy can be physically exhausting and mentally draining.

How will pembrolizumab benefit cancer patients?

Pembrolizumab, according to doctors, will make cancer therapy and treatment more convenient for patients, and it can also bring down waiting times. It is one of the most successful cancer drugs and has been celebrated as a game-changer in treating several tumour types. The NHS uses the drug to treat 14 types of cancer, such as lung, breast, bowel, womb, stomach, head and neck, and melanoma.

The first-ever patient to receive pembrolizumab was Shirley Xerxes, 89, from St Albans, Hertfordshire, who was suffering from bowel cancer. She spoke several times about how it changed her will to live and how little time it took.

How does pembrolizumab work?

Pembrolizumab tells the immune system to recognise and kill cancer cells. It can fight head and neck, lung, breast, and cervical cancer. The drug is administered every three weeks as a one-minute injection, or it is given every six weeks as a two-minute injection, depending on the cancer type.